Literature DB >> 33651441

Heroin Use Cannot Be Measured Adequately with a General Population Survey.

Peter Reuter1, Jonathan P Caulkins2, Greg Midgette1.   

Abstract

BACKGROUND: Globally, heroin and other opioids account for more than half of deaths and years-of-life-lost due to drug use and comprise one of the four major markets for illegal drugs. Having sound estimates of the number of problematic heroin users is fundamental to formulating sound health and criminal justice policies. Researchers and policy makers rely heavily on general population surveys (GPS), such as the U.S. National Survey on Drug Use and Health (NSDUH), to estimate heroin use, without confronting their limitations. GPS-based estimates are also ubiquitous for cocaine and methamphetamine, so insights pertaining to GPS for estimating heroin use are relevant for those drug markets as well. ANALYSIS: Four sources of potential errors in NSDUH are assessed: selective non-response, small sample size, sampling frame omissions and under-reporting. An alternative estimate drawing on a variety of sources including a survey of adult male arrestees is presented and explained. Other approaches to prevalence estimation are discussed.
FINDINGS: Under-reporting and selective non-response in NSDUH are likely to lead to substantial underestimation. Small sample size leads to imprecise estimates and erratic year-to-year fluctuations. The alternative estimate provides credible evidence that NSDUH underestimates the number of frequent heroin users by at least three quarters and perhaps much more. IMPLICATIONS: GPS, even those as strong as NSDUH, are doomed by their nature to estimate poorly a rare and stigmatized behavior concentrated in a hard-to-track population. Though many European nations avoid reliance on these surveys, many others follow the US model. Better estimation requires models that draw on a variety of data sources including GPS to provide credible estimates. Recent methodological developments in selected countries can provide guidance. Journals should require researchers to critically assess the soundness of GPS estimates for any stigmatized drug-related behaviors with low prevalence rates. This article is protected by copyright. All rights reserved.

Entities:  

Keywords:  drug policy; heroin; hidden populations; opioids; prevalence estimation

Year:  2021        PMID: 33651441     DOI: 10.1111/add.15458

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  15 in total

1.  Caution Is Necessary When Estimating Treatment Need for Opioid Use Disorder Using National Surveys.

Authors:  Elizabeth D Nesoff; Silvia S Martins; Joseph J Palamar
Journal:  Am J Public Health       Date:  2022-02       Impact factor: 9.308

2.  Kratom Use Is Underestimated, but Prevalence Still Appears to Be Low.

Authors:  Joseph J Palamar
Journal:  Am J Prev Med       Date:  2022-01       Impact factor: 5.043

3.  Toward a typology of hallucinogen users in the United States.

Authors:  Christopher P Salas-Wright; James C Hodges; Audrey Hang Hai; Abdulaziz Alsolami; Michael G Vaughn
Journal:  Drug Alcohol Depend       Date:  2021-10-28       Impact factor: 4.492

4.  Estimating the Prevalence of Substance Use Disorders in the US Using the Benchmark Multiplier Method.

Authors:  Ramin Mojtabai
Journal:  JAMA Psychiatry       Date:  2022-09-21       Impact factor: 25.911

5.  Socioeconomic inequalities and Black/White disparities in US cocaine-involved overdose mortality risk.

Authors:  Manuel Cano; Christopher P Salas-Wright; Sehun Oh; Lailea Noel; Dora Hernandez; Michael G Vaughn
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2022-03-06       Impact factor: 4.519

Review 6.  Responding to the opioid crisis in North America and beyond: recommendations of the Stanford-Lancet Commission.

Authors:  Keith Humphreys; Chelsea L Shover; Christina M Andrews; Amy S B Bohnert; Margaret L Brandeau; Jonathan P Caulkins; Jonathan H Chen; Mariano-Florentino Cuéllar; Yasmin L Hurd; David N Juurlink; Howard K Koh; Erin E Krebs; Anna Lembke; Sean C Mackey; Lisa Larrimore Ouellette; Brian Suffoletto; Christine Timko
Journal:  Lancet       Date:  2022-02-02       Impact factor: 202.731

7.  Associations of Lifetime Nonmedical Opioid, Methamphetamine, and Kratom Use within a Nationally Representative US Sample.

Authors:  Kirsten E Smith; Jeffrey M Rogers; Justin C Strickland
Journal:  J Psychoactive Drugs       Date:  2021-11-29

8.  Stimulant-related incident surveillance using emergency medical service records in Massachusetts, 2013-2020.

Authors:  Amy Bettano; Brandon Del Pozo; Dana Bernson; Joshua A Barocas
Journal:  Drug Alcohol Depend       Date:  2022-04-14       Impact factor: 4.852

9.  Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort.

Authors:  Jake R Morgan; Alexander Y Walley; Sean M Murphy; Avik Chatterjee; Scott E Hadland; Joshua Barocas; Benjamin P Linas; Sabrina A Assoumou
Journal:  Drug Alcohol Depend       Date:  2021-05-21       Impact factor: 4.852

10.  Invited Commentary: Drug Checking for Novel Insights Into the Unregulated Drug Supply.

Authors:  Nabarun Dasgupta; Mary C Figgatt
Journal:  Am J Epidemiol       Date:  2022-01-24       Impact factor: 4.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.